NovaBay Pharmaceuticals Inc (NBY) - Total Liabilities
Based on the latest financial reports, NovaBay Pharmaceuticals Inc (NBY) has total liabilities worth $31.86 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore NBY net asset momentum to track the company's year-over-year net asset growth rate.
NovaBay Pharmaceuticals Inc - Total Liabilities Trend (2003–2025)
This chart illustrates how NovaBay Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See NBY free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
NovaBay Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of NovaBay Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Freemelt Holding AB
ST:FREEM
|
Sweden | Skr19.93 Million |
|
Champ Resto Indonesia PT
JK:ENAK
|
Indonesia | Rp827.02 Billion |
|
Snail, Inc. Class A Common Stock
NASDAQ:SNAL
|
USA | $76.56 Million |
|
Ihuman Inc
NYSE:IH
|
USA | $384.80 Million |
|
Fridenson
TA:FRDN
|
Israel | ILA185.56 Million |
|
Avante Logixx Inc
V:XX
|
Canada | CA$10.84 Million |
|
Industrial Investment Trust Limited
NSE:IITL
|
India | Rs41.98 Million |
|
Enjoei S.A
SA:ENJU3
|
Brazil | R$133.21 Million |
Liability Composition Analysis (2003–2025)
This chart breaks down NovaBay Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NovaBay Pharmaceuticals Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NovaBay Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NovaBay Pharmaceuticals Inc (2003–2025)
The table below shows the annual total liabilities of NovaBay Pharmaceuticals Inc from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $31.86 Million | +796.99% |
| 2024-12-31 | $3.55 Million | -37.90% |
| 2023-12-31 | $5.72 Million | -2.14% |
| 2022-12-31 | $5.84 Million | -57.67% |
| 2021-12-31 | $13.81 Million | +372.84% |
| 2020-12-31 | $2.92 Million | -71.50% |
| 2019-12-31 | $10.25 Million | +132.52% |
| 2018-12-31 | $4.41 Million | -41.12% |
| 2017-12-31 | $7.49 Million | -9.60% |
| 2016-12-31 | $8.28 Million | -18.62% |
| 2015-12-31 | $10.18 Million | +78.85% |
| 2014-12-31 | $5.69 Million | -20.26% |
| 2013-12-31 | $7.13 Million | +37.56% |
| 2012-12-31 | $5.19 Million | -21.65% |
| 2011-12-31 | $6.62 Million | +31.70% |
| 2010-12-31 | $5.03 Million | +20.30% |
| 2009-12-31 | $4.18 Million | -36.93% |
| 2008-12-31 | $6.62 Million | -31.01% |
| 2007-12-31 | $9.60 Million | -4.49% |
| 2006-12-31 | $10.05 Million | +3142.90% |
| 2005-12-31 | $310.00K | -39.57% |
| 2003-12-31 | $513.00K | -- |
About NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. T… Read more